If requesting this service, please send the following documentation to support medical necessity:
• Last 2 years of neurology notes • Most recent clinical note from requesting provider
Background
Migraine headache is a common primary headache disorders that is characterized by a variety of symptoms such as nausea, vomiting, visual disturbances, and sensitivity to light and sounds. In the United States, approximately 18% of women and 6% of men have experienced at least one migraine in the previous year. Standard treatment for migraine involves identification and avoidance of triggers, and the use of pharmacotherapy to treat acute attacks and prevent further attacks (Goadsby 2010 , Silberstein 2004 .
Surgical treatment for migraine headache has been proposed for patients who are not receiving adequate benefit from standard treatment options. This approach was originally discovered as an unanticipated benefit of cosmetic surgery. The first step to determining whether the patient is a candidate for surgery is to identify trigger sites. Most investigators use Botox to identify the trigger site; however, local nerve blocks can also be used. Patients who experience complete elimination or at least 50% improvement in intensity and/or frequency of headaches are considered candidates for surgery. The surgical approach varies by trigger site and involves removal of certain facial muscles, severing of a facial nerve, and/or surgical modification of the sinuses (Kung 2011).
Medical Technology Assessment Committee (MTAC)

Surgical Deactivation of Trigger Sites for Treatment of Migraine Headaches
02/11/2013: MTAC REVIEW Evidence Conclusion: A RCT that included 125 subjects evaluated the safety and efficacy of surgical deactivation of migraine headache trigger sites. Patients in the treatment group were injected with Botox to identify trigger sites. Patients were eligible for surgery if they experienced at least 50% improvement in the intensity and/or frequency of headaches from the Botox lasting at least 4 weeks. Ninety-one patients out of the 100 patients in the treatment group underwent surgery. Patients in the control group receive injections of saline. After one year 31 patients in the treatment group and 3 patients in the control group experienced complete elimination. Both groups experienced significant improvement in headache intensity and duration compared to baseline; however, only the treatment group experienced a significant improvement in headache frequency. Compared to the control group,
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patients who received surgery experienced significantly greater reductions in headache frequency, intensity, and duration at one year. The most common surgical complications were: nasal dryness, rhinorrhea, recurrence of septal deviation, scalp itching, and minor hair loss. This study had several limitations: the inclusion and exclusion criteria were not provided, an ITT analysis was not performed, power was not assessed, the outcome data was self-reported, and it is not stated whether patients were taking pharmacotherapy during the trial (Guyuron 2005). Patients in the treatment group were followed for 5-years to determine the long-term safety and efficacy of surgery. Ten patients in the treatment group who underwent additional surgery were excluded from the analysis, leaving 69 patients. Results from this observational follow-up study suggest that the improvements in headache frequency, duration, and intensity that were achieved at 1 year were maintained at 5 years (Guyuron 2011). A more recent RCT that included 75 subjects also evaluated the safety and efficacy of surgical deactivation of migraine headache trigger sites. Patients underwent injections of Botox to identify the trigger site. Patients who experienced complete elimination or at least 50% improvement in intensity and/or frequency of headaches were candidates for surgery. Patients were then randomized to receive either surgery based on migraine trigger site (frontal, temporal, or occipital) or sham surgery. Twenty-eight (57%) patients who underwent surgery experienced complete elimination compared to 1 (4%) who underwent sham surgery. Both groups experienced significant improvements in headache frequency and intensity from baseline. The treatment group also experienced a significant improvement in headache duration from baseline. The treatment group experienced significantly greater reductions in headache frequency and intensity compared to the control group at one year. There was no significant difference between the treatment and the control group in headache duration. The most common adverse events were temporary hollowing and intense itching. This trial had several limitations: it was a small trial and power was not assessed, outcomes were self-reported, and it is not stated whether patients were taking pharmacotherapy during the trial (Guyuron 2009). 
Headache outcomes at 1 year (Guyuron 2005)
